Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients

Juan David Cala-García*,1, Juan David Sierra-Bretón¹, Jorge Eduardo Cavelier-Baiz¹, Álvaro A Faccini-Martínez²¹ & Carlos Eduardo Pérez-Díaz¹,3
¹Infectious diseases, Clínica de Marly, Bogotá 110231, Colombia
²Asociación Colombiana de Infectología, Bogotá 110111, Colombia
³Infectious diseases, Hospital La Samaritana, Bogotá 110321, Colombia
*Author for correspondence: Tel.: +57 311 238 6975; juancala97@hotmail.com

Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivation of the immune system, better known as cytokine storm syndrome. Tocilizumab has been proposed to treat COVID-19 severe cases associated to ARDS.

Results & methodology: Here we present two successful cases of tocilizumab administration in two COVID-19 patients with prior administration of antiviral therapy (hydroxychloroquine, azithromycin, lopinavir and ritonavir) with adequate response and resolution of ARDS, septic shock and severe pneumonia within the first 72 h. Discussion & conclusion: This case supports the usage of tocilizumab as an effective therapy in COVID-19 associated cytokine storm syndrome. Further studies should be done in order to assess its effectiveness and security.

In December 2019, global health took a drastic change with the appearance of a novel coronavirus in Wuhan, China. Later, this virus was identified as SARS coronavirus 2 (SARS-CoV-2) and the disease was named coronavirus disease 2019 (COVID-19) [1]. On 1 July 2020, 10,446,353 cases have been confirmed taking over 511,037 lives worldwide, and in Colombia, 102,009 cases have been confirmed with 3470 attributable deaths [2].

COVID-19 has a wide spectrum of disease, ranging from an asymptomatic/mild respiratory infection, to a severe pneumonia with the development of acute respiratory distress syndrome (ARDS) [1]. Although pathophysiology is not completely clear, it has been suggested that in severe cases, a disproportionate immune response might lead to a cytokine storm syndrome (CSS), resulting in damage of the lung parenchyma, pneumonitis, ARDS, viral septic shock and death [3]. This being said, tocilizumab, an IL-6 antagonist, has been proposed for treatment in severe cases [4,5].

Here, we present two Colombian COVID-19 cases successful recovery of severe pneumonia with ARDS after tocilizumab administration in a reference center in Bogotá, Colombia. Administration of tocilizumab was approved as a compassionate off-label protocol under the supervision of the scientific committee of Clínica de Marly medical center. Prior consents were obtained before the administration of the IL-6 antagonist.

Case reports
Case A
A 58-year old female with unknown past medical history who presented with 10 days of dry cough, sore throat, fever and dyspnea. At admission with SaO2 of 85% and costal retractions. Chest computed tomography (CT)
evidenced peripheral ground glass opacities (Figure 1A), and initial lab tests were significant for elevated C-reactive protein (CRP) (>9 mg/dl) leukocytosis (20.100 × 10^3 /μl), neutrophilia (17.100 × 10^3 /μl), elevated lactate dehydrogenase (LDH) (396 U/l) and D-dimer (1.63 μg/ml). Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) was performed on an oropharyngeal swap and was found positive for SARS-CoV-2 infection. Treatment with hydroxychloroquine and azithromycin was started, but on day 5 of hospitalization the patient developed septic shock with respiratory failure, with a severe impairment of oxygenation with a PaO2/FiO2 66. The patient was transferred to the ICU in the 7th day of hospitalization; intubation was performed, lopinavir/ritonavir was added as an antiviral treatment and norepinephrine drip was started. During ICU hospitalization, inflammatory markers (D-dimer, LDH, ferritin, CRP) were constantly rising (Table 1), and in the 8th day of hospitalization, 400 mg of tocilizumab intravenous were initiated. After administration, CRP, D-dimer, LDH and ferritin started trending down after 48 h (Table 1), ventilatory support was gradually weaned and extubating was achieved on the 16th day of hospitalization. Patient was discharged on her 21st day of hospitalization (31st day of symptoms onset).

#### Table 1. Laboratory work sheet of case A.

|                      | D1  | D3  | D5  | D8  | D10 | D12 | D14 | D18 | D21 |
|----------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| WBC (×10^3 per μl)  |     |     |     |     |     |     |     |     |     |
| Normal values: 4.6–10.2 | 20.1| 10.2| 9.77| 8.15| 6.51| 6.36| 6.39| 6.22| 6.38|
| PMN (×10^3 per μl)  |     |     |     |     |     |     |     |     |     |
| Normal values: 1500–8000 | 17.1| 8.41| 7.95| 5.72| 3.91| 3.71| 3.26| 3.60| 3.28|
| Lymphocytes (×10^3 per μl) | 2.05| 1.16| 1.34| 1.71| 2.12| 2.25| 2.42| 1.970| 2.52|
| Platelets (×10^3 per μl) | 246 | 240 | 276 | 323 | 383 | 414 | 397 | 292  | 402 |
| Hemoglobin (g/dl)    |     |     |     |     |     |     |     |     |     |
| Normal values: 12–16.8 | 15.5| 12.4| 13.5| 11.7| 13  | 13  | 14.3| 12.6 | 16  |
| LDH (U/l)            |     |     |     |     |     |     |     |     |     |
| Normal values: 120–246 |     | 396 | 335 | 311 | 333 | 339 | 376 |     |     |
| D Dimer (μg/ml)      |     |     |     |     |     |     |     |     |     |
| Normal values: <0.57 | 1.63| >5  | >5  | >5  | >5  | >5  | 3.8 |     |     |
| Ferritin (ng/ml)     |     |     |     |     |     |     |     |     |     |
| Normal values: <400  | 1110| >1000|     |     |     |     |     | 1050|     |
| Troponin (ng/l)      |     |     |     |     |     |     |     |     |     |
| Normal values: <11   | 4.1 | 4.62|     |     |     |     |     |     |     |
| C-reactive protein (mg/dl) | >9 | 8.4 | >9  | 1.82| 0.8 |     |     |     |     |

Column highlighted shows the day tocilizumab was administered.

D: Day since hospital admission; LDH: Lactate dehydrogenase; PMN: Neutrophil; WBC: White blood cell.

Figure 1. Radiological findings on chest computed tomography from case A. (A) On admission (day 0 of hospitalization, day 10 of symptom’s onset). (B) On discharge (day 21 of hospitalization, day 31 of symptom’s onset).
Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab

Case Report

A 50-year-old female patient with past medical history of hypothyroidism who presented with 9 days of fever, chills, headache and dyspnea. Upon arrival, she was found on a stable clinical condition only with audible rales at physical examination. Chest CT showed ground glass opacities with a peripheral distribution, with greater compromise of bases and areas of crazy paving (Figure 2A), and initial lab tests showed lymphopenia ($1010 \times 10^3$ cells/μl), and lightly elevated LDH (343 U/l), D-dimer (0.88 μg/ml) and CRP (5.09 mg/dl) (Table 2). SARS-CoV-2 RT-qPCR was performed on an oropharyngeal swab which was positive. Hydroxychloroquine/azithromycin was started. However, during hospitalization, her condition worsened with new onset of dyspnea, fever spikes and diarrhea.

**Case B**

A 50-year-old female patient with past medical history of hypothyroidism who presented with 9 days of fever, chills, headache and dyspnea. Upon arrival, she was found on a stable clinical condition only with audible rales at physical examination. Chest CT showed ground glass opacities with a peripheral distribution, with greater compromise of bases and areas of crazy paving (Figure 2A), and initial lab tests showed lymphopenia ($1010 \times 10^3$ cells/μl), and lightly elevated LDH (343 U/l), D-dimer (0.88 μg/ml) and CRP (5.09 mg/dl) (Table 2). SARS-CoV-2 RT-qPCR was performed on an oropharyngeal swab which was positive. Hydroxychloroquine/azithromycin was started. However, during hospitalization, her condition worsened with new onset of dyspnea, fever spikes and diarrhea.

**Table 1. Laboratory work sheet of case B.**

|                | D1     | D3     | D5     | D7     | D9     | D11    | D13    | D15    |
|----------------|--------|--------|--------|--------|--------|--------|--------|--------|
| WBC ($\times 10^3$ per μl) | 4.66   | 5.67   | 7.59   | 8.14   | 8.63   | 7.94   | 8.63   | 7.67   |
| Normal values: 4.6–10.2 |        |        |        |        |        |        |        |        |
| PMN ($\times 10^3$ per μl) | 3.20   | 4.20   | 6.43   | 5.79   | 6.02   | 6.32   | 6.23   | 4.51   |
| Normal values: 1500–8000 |        |        |        |        |        |        |        |        |
| Lymphocytes ($\times 10^3$ per μl) | 1.01   | 1.00   | 0.718  | 1.41   | 1.60   | 0.91   | 1.24   | 1.87   |
| Normal values: 1000–4000 |        |        |        |        |        |        |        |        |
| Platelets ($\times 10^3$ per μl) | 207    | 210    | 207    | 374    | 366    | 423    | 418    | 415    |
| Normal values: 142–424 |        |        |        |        |        |        |        |        |
| Hemoglobin (g/dl) | 14.7   | 12     | 9.8    | 12.5   | 12.7   | 11.8   | 12.5   | 12.8   |
| Normal values: 12–16.8 |        |        |        |        |        |        |        |        |
| LDH (U/l) | 343    | 316    | 364    | 395    | 505    | 328    | 351    | 327    |
| Normal values: 120–246 |        |        |        |        |        |        |        |        |
| D Dimer (μg/ml) | 0.88   | 1.18   | 0.88   | 1.19   | 2.7    | 3.66   | 2.6    | 1.78   |
| Normal values: <0.57 |        |        |        |        |        |        |        |        |
| Ferritin (ng/ml) | 183    | 170    | 226    | 370    | 496    | 572    | 598    | 452    |
| Normal values: <400 |        |        |        |        |        |        |        |        |
| Troponin (ng/l) | 3.7    | 17.1   | 5.5    | 8.6    | 1.55   | <1–5   | <1.5   |        |
| Normal values: <11 |        |        |        |        |        |        |        |        |
| C-reactive Protein (mg/dl) | 5.09   | 8.9    | >9     | >9     | >9     | 3.25   | 0.79   | <0.5   |
| Normal values: <1.5 |        |        |        |        |        |        |        |        |

Column highlighted shows the day tocilizumab was administered.
D: Day since hospital admission; LDH: Lactate dehydrogenase; PMN: Neutrophil; WBC: White blood cell.

**Figure 2. Radiological findings on chest computed tomography from case B. (A) On admission (day 0 of hospitalization, day 9 of symptom’s onset). (B) On discharge (day 16 of hospitalization, day 25 of symptom’s onset).**
Lopinavir/ritonavir was started but pneumonia kept progressing with compromise of oxygenation evidenced by lowering of PaO2/FiO2. The patient was transferred to the ICU in the 4th day of hospitalization to provide invasive mechanical ventilation and norepinephrine administration. LDH, ferritin, D-dimer and CRP kept rising (Table 2), and 600 mg of tocilizumab intravenous was administrated on the 7th day of hospitalization. Inflammatory markers kept rising on the first 2 days after tocilizumab, with later regression of D dimer, ferritin, CRP and LDH. Patient improved her clinical condition and was taken out of the ICU on the 12th day of hospitalization and was discharged on the 16th day of hospitalization with low oxygen support (25th day of symptoms onset). Control chest CT showed regression of ground glass opacities with significant improvement (Figure 2B).

Discussion

We present two successful cases of tocilizumab treatment in Colombian patients with COVID-19 severe pneumonia and ARDS. Both patients, presumably developed CSS which resolved after receiving IL-6 antagonist. Fortunately, none of our patients developed any adverse reaction related to tocilizumab.

Although it is not entirely clear how SARS-CoV-2 causes severe pneumonia, septic shock, ARDS or even death, it has been suggested that one of the main causes that affects patients is the immune response, specifically, the development of CSS [3,6]. It has been established that SARS-CoV-2 targets cells expressing angiotensin-converting enzyme-2 receptor [7,8], which explains why this virus generates a lower respiratory tract infection, but still, it is not clear what marks susceptibility to develop a severe infection. Patients with severe infections have shown to have high inflammatory markers such as IL-6, CRP, D dimer, LDH and lymphopenia [1,5,9]. Initially, the immune system will start an innate response, recognizing pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), which will increase IFN-1 production and then, generating an activation of LT CD4+ Th1, CD8+ and LB cells [7]. In cases in which there is an overexpression of the immune system, overproduction of proinflammatory cytokines such as IL-1, IL-6, IL-8, TNF-α will disrupt the integrity of blood vessels, and will create vascular leakage [10], eventually causing alveolar flooding [11]. This correlates well with findings on autopsies on COVID-19 deceased patients which evidences diffuse alveolar damage, proteinaceous exudates, vascular congestion, mononuclear inflammatory infiltrates, mostly lymphocytes and multinucleated giant cells [12].

Tocilizumab is an IL-6R monoclonal antibody, which is currently used mainly for the management of rheumatoid arthritis, and nowadays, with an increase of its use for pathologies associated with CSS such as hemophagocytic lymphohistiocytosis, macrophage activation syndrome, or chimeric antigen receptor (CAR)-T cell therapy adverse reactions [10,13]. Since one of the principal reasons of developing acute lung injury and ARDS in COVID-19 pneumonia is the overexpression of the immune system, blocking IL-6 would stop the activation of innate immune cells [like neutrophils and macrophages] [6], which eventually leads to the development of CSS and therefore, have a decrease in mortality in critically ill patients [14,15].

Currently, there is a Phase III trial (ChiCTR2000029765) in China studying the efficacy and safety of tocilizumab as a treatment for SARS-CoV-2 pneumonia [16], and there has been reported successful usage of tocilizumab lowering inflammatory markers, increasing lymphocyte count and improving ventilatory patters, as well as improvement of radiologic pattern [4,5,17], findings that correlate well with our described patients.

Although there is good evidence of tocilizumab as a target therapy in critically ill COVID-19 cases, there have also been reported failures in tocilizumab administration as treatment of severe illness from COVID-19, in which progression to hemophagocytic lymphohistiocytosis was evidenced, and even development of severe complications such as viral myocarditis was shown [18]. Radbel et al. hypothesized that the development of viral myocarditis could be attributed to the decreased lymphocyte maturation due to the IL-6 antagonism [18], raising the concern of immunotherapy in COVID-19 cytokine storm syndrome (CSS). Fortunately, none of our patients developed any complications of immunotherapy, instead they evolved to a complete resolution of ARDS, septic shock and severe pneumonia within the first 72 h.

Although tocilizumab seems like a good option for CSS in COVID-19 pneumonia [13,19], special consideration should be given to its side effects, principally immunosuppression. For tropical countries such as Colombia, we consider screening of TB with QuantiFERON TB before giving tocilizumab in order to prevent possible exacerbations [20].

To summarize, we report the usage of tocilizumab in two critically ill patients with COVID-19 pneumonia, with prior use of antiviral therapy (hydroxychloroquine, azithromycin, lopinavir and ritonavir) with adequate response and resolution of ARDS, septic shock and severe pneumonia within the first 72 h, supporting it’s usage as a possible...
treatment in a pandemic urging for safe and effective solutions in the setting of critically ill patients. Further randomized controlled clinical trials should be done in order to assess the real effectivity and safety of tocilizumab treatment in COVID-19.

There are still many things we have to learn in order to treat COVID-19 correctly. One of the strongest hypotheses that has been suggested in the academic world is the association of a disproportionate immune response with a severe viral pneumonia and the development of ARDS. Impacting in the inflammatory response, and, in this case, stopping the development of the CSS in COVID-19 might be the correct direction to impact on morbidity and mortality in COVID-19 severe cases.

Executive summary
- Cytokine storm syndrome is a reality in severe cases of COVID-19.
- Tocilizumab can be a suitable and effective therapy for severe cases of COVID-19 associated with acute respiratory distress syndrome.
- In our report, tocilizumab was associated with a resolution of acute respiratory distress syndrome in the first 72 h after its administration.
- Even though tocilizumab was an effective therapy in our patients, special consideration has to be established for the associated immunosuppression.
- For tropical countries such as Colombia, we consider screening of TB with QuantiFERON TB before giving tocilizumab in order to prevent possible exacerbations.
- Further research should be done in order to establish tocilizumab’s effectiveness and safety.

Author contributions
All authors mentioned above made substantial contribution to the design of the work, drafting the work (with the exception of AA Faccini-Martinez and C Perez who revised the manuscript and made critical modifications for the submission); approved the final version of the manuscript to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Acknowledgments
We would like to thank to all the COVID-19 research group from Clínica de Marly, and especially, Dr Luis Eduardo Cavelier-Castro for his support, leadership and valuable attributions.

Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval. informed consent has been obtained from the participants involved.

References
Papers of special note have been highlighted as: ● of interest

1. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46(5), 846–848 (2020).
2. Colombian Ministry of Health. CORONAVIRUS (COVID-19). www.minsalud.gov.co/salud/pública/PET/Paginas/Covid-19_copia.aspx
3. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J. Infect. 80(6), 607–613 (2020).
4. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality]. Int. J. Antimicrob. Agents. 105954 (2020) (Epub ahead of print).doi:10.1016/j.ijantimicag.2020.105954

● Important summary of cytokine storm syndrome (CSS) development in COVID-19 and consider tocilizumab as a possible pharmacologic intervention.
5. Xu X, Han M, Li T et al. Effective treatment of severe COVID-19 patients with tocilizumab. *Proc. Natl Acad. Sci. USA* 117(20), 10970–10975 (2020).
6. Chakraborty C, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Agoramoorthy G. Consider TLR5 for new therapeutic development against COVID-19. *J. Med. Virol.* (2020) (Epub ahead of print). doi:10.1002/jmv.25997
7. Astuti I, Yrsafl. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. *Diabetes Metab. Syndr.* 14(4), 407–412 (2020).
8. Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. *Eur. Rev. Med. Pharmacol. Sci.* 24(7), 4016–4026 (2020).
9. Richardson S, Hirsch JS, Narasimhan M et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. *JAMA* e206775 (2020) (Epub ahead of print). doi:10.1001/jama.2020.6775
10. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. *Immunotherapy* 8(8), 959–970 (2016).

- States how IL-6 is directly involved with the development of CSS and it's consequences in the human body.

11. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. *Am. J. Emerg. Med.* 26(6), 711–715 (2008).
12. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir. Med.* 8(4), 420–422 (2020).
- Pathological findings on autopsy of COVID-19 patients which demonstrates the consequences of CSS development in COVID-19.
13. Chakraborty C, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Agoramoorthy G. COVID-19: consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients. *J. Med. Virol.* (2020) (Epub ahead of print). doi:10.1002/jmv.26078
14. Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19?. *J. Transl. Med.* 18, 164 (2020).
15. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 395(10229), 1033–1034 (2020).
16. Chinese clinical trial register. Chinese Clinical Trial Register (ChiCTR) – The world health organization international clinical trials registered organization registered platform. www.chictr.org.cn/showprojen.aspx?proj=49409
17. Cellina M, Orsi M, Bombaci F, Sala M, Marino P, Oliva G. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. *Diagn. Intens. Imaging* 101(5), 323–324 (2020).
18. Radbel J, Narayanan N, Bhant PJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report. *Chest* 30764–30769 (2020) S0012–3692(20). (Epub ahead of print). doi:10.1016/j.chest.2020.04.024
- Although tocilizumab has been suggested as an effective treatment in COVID-19, there is evidence that it could be related to complications in severely affected patients.
19. Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Chakraborty C. Tocilizumab: a therapeutic option for the treatment of cytokine storm syndrome in COVID-19. *Arch. Med. Res.* (2020) (Epub ahead of print). doi:10.1016/j.arcmed.2020.05.009
20. Alghari SK, Acuña VS. Supportive treatment with tocilizumab for COVID-19: a systematic review. *J. Clin. Virol.* 127, 104380 (2020).
- Evaluates tocilizumab as a good candidate for treating COVID-19 severe cases. It also mentions it's considerations and possible side effects that should be taken into account.